对与偏头痛治疗中eptinezumab相关的不良事件的全面安全分析
Junchen Chen1, Shunqiu Huang1, Yashi Chen1
1Department of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, No. 57 Changping Road, Shantou, 515041, Guangdong, China.
Scientific reports
|July 8, 2025
概括
针对偏头痛的CGRP向疗法EPTINESUMAB显示出潜力,但需要进一步评估安全性. 现实世界的数据和临床试验表明一些不良事件,需要持续的研究,以全面理解.
科学领域:
- 神经学 神经学
- 药物监督 药物监督 药物监督
- 临床试验 临床试验
背景情况:
- 偏头痛严重影响患者的生活质量.
- 素基因相关 (CGRP) 向疗法,如eptinezumab,提供新的治疗途径.
- 对于CGRP抑制剂来说,全面的安全性和有效性数据至关重要.
研究的目的:
- 评估eptinezumab在偏头痛治疗中的安全性和有效性.
- 分析现实世界的不良事件数据和临床试验结果.
- 确定与eptinezumab治疗相关的潜在安全信号和风险.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库 (2020-2024) 的药监测分析.
- 六项涉及3,148名参与者的临床试验的系统审查和元分析.
- 统计分析包括报告几率 (ROR) 和相对风险 (RR) 的计算.
主要成果:
- FAERS确定了5306个不良事件,其中"药物无效"和"偏头痛"是关键信号. 观察到过敏反应和内压升高的SAEs.
- 分析显示,与安慰剂相比,整体不良事件风险没有增加 (RR=1.02),但严重不良事件 (SAE) 的发生率更高 (RR=2.87).
- 使用eptinezumab的上呼吸道感染更频繁 (RR=1.49),而头,恶心和疲劳没有显著差异.
结论:
- 埃普特尼祖马布显示出作为一种针对CGRP的偏头痛疗法的潜力.
- 现实世界的数据表明了特定的不良事件概况,包括药物的无效性和SAE的潜力.
- 需要进一步的研究,以了解eptinezumab在不同人群和现实世界的环境中的安全性.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
01:19Pharmacovigilance
999
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
999